Favipiravir ameliorates bleomycin-induced pulmonary fibrosis by reprogramming M1/M2 macrophage polarization-Reference-Cited by-同舟云学术

Favipiravir ameliorates bleomycin-induced pulmonary fibrosis by reprogramming M1/M2 macrophage polarization

Published:2024-04 Issue: Volume:131 Page:111774
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Zhang Ruiqin,Jiang Qiuyan,Gao Shaoyan,Zhang Huizhe,Xia Qin,Liu Bowen,Zhu Jingyan,Jiang Haixia,Zhao Ruixi,Dong Huixuan,Li Xiaohe,Zhang Yanping,Yang Cheng,Gu Xiaoting,Sun Liang,Zhou Honggang^ORCID

Publisher

Elsevier BV

Reference22 articles.

1. Corona virus disease 2019 (COVID-19) diagnostic tests: a glimpse;Islam;Mymensingh Med J,2022

2. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence;Wack;J Am Acad Dermatol,2021

3. Pulmonary fibrosis secondary to COVID-19: a narrative review;Tanni;Expert Rev Respir Med,2021

4. Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis;Velagacherla;Life Sci,2022

5. Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF);Saito;J Thorac Dis,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PBMC-mediated modulation of macrophage polarization in RAW264.7 cells through STAT1/STAT6 signaling cascades;International Immunopharmacology;2024-09

2. Repurposing existing drugs for the treatment ofCOVID-19/SARS-CoV-2: A review of pharmacological effects and mechanism of action;Heliyon;2024-08

3. Advances in common in vitro cellular models of pulmonary fibrosis;Immunology & Cell Biology;2024-05-07